The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Polymer coatings on drug-eluting stents: Samson’s hair and Achilles’ heel?

EuroIntervention 2013;9:302-305. DOI: 10.4244/EIJV9I3A51

1. Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands; 2. Deutsches Herzzentrum, Technische Universität, Munich, Germany; 3. DZHK (German Centre for Cardiovascular Research), partner site
Drug-eluting stents (DES) minimise the risk of in-stent restenosis by means of controlled, local delivery of antiproliferative drugs from a thin layer of coating applied to a rigid stent backbone. In this respect, polymer coatings have proven largely indispensable for the control of drug release kinetics and the optimisation of DES efficacy. Investigation of polymer-free stent platforms has typically yielded comparatively lower levels of neointimal suppression by virtue of rapid drug dissociation in the initial hours and days after stent implantation1. Indeed, all of the currently available FDA-approved DES devices control drug release by use of durable polymer coatings2,3. On ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent